After opening, the bottle remains sterile for 6 months, so continue use until then if required
Research indicates that semaglutide and testosterone do not have direct pharmacological interactions, but their combined metabolic effects require informed clinical management
Has Retatrutide Been Approved by the FDA
For these patients, initiating weight loss injections may be considered if: The potential metabolic benefits (improved diabetes control, cardiovascular risk reduction, weight loss) substantially outweigh gallbladder risks Close monitoring is feasible with regular clinical follow-up Patients understand warning signs of gallbladder complications The rate of weight loss can be moderated through dosing strategies Conversely, patients with symptomatic gallstones experiencing biliary colic (right upper quadrant pain after meals), previous episodes of cholecystitis, or complications such as pancreatitisgenerally should undergo evaluation by a gastroenterologist or surgeon before starting weight loss injections
GLP-1s are becoming a bigger part of weight management
Conclusion Otolaryngologists should be aware and monitor for possible otolaryngologic side effects, particularly PETD, with GLP-1 RA use.
